# Research Alliance Corp III (RACC) — capital_raise/private_placement [pending]
Source: SEC API (secapi.ai) · situation sit_aeeeb9b5d351137ddf32 · retrieved 2026-08-11T15:52:45.196Z

## Overview
OHB Pediatrics Ltd. is a clinical-stage biopharmaceutical company engaged in the development of rugonersen, an antisense oligonucleotide currently in Phase 3 clinical development for the treatment of Angelman syndrome, a rare genetic neurodevelopmental disorder.

Research Alliance Corporation III (RACC), a Cayman Islands SPAC, entered into a Business Combination Agreement on July 26, 2026 to acquire 100% of OHB Pediatrics Ltd., a clinical-stage biopharmaceutical company developing rugonersen for Angelman syndrome, in exchange for newly issued RACC common stock. The transaction values the Company at a base equity value of $160,000,000, with an Adjusted Equity Value that includes the Company SAFE Amount (principal of $45,000,000 plus accrued interest at 8% per annum). The Closing Consideration equals the Adjusted Equity Value divided by $10.00 per share. Concurrently, RACC is raising $55,000,000 in PIPE financing from qualified institutional buyers at $10.00 per share (or via pre-funded warrants). The transaction is expected to close in the second half of 2026, subject to RACC shareholder approval, regulatory clearances including HSR Act approval, and other customary closing conditions. RACC will domesticate from the Cayman Islands to Delaware prior to closing.

## Terms
- Counterparty: OHB Pediatrics Ltd. · Deal value: $160.0M · Consideration: stock · Stake: 100% · Price/share: $10

## Key dates
- Announced 2026-07-27

## Timeline
- 2026-07-27 · 8-K (0001193125-26-316954): 8-K - Research Alliance Corp III — *OHB Pediatrics Ltd. is a clinical-stage biopharmaceutical company engaged in the development of rugonersen, an antisense oligonucleotide currently in Phase 3 clinical development for the treatment of Angelman syndrome, a rare genetic neurodevelopmental disorder.* Research Alliance Corporation III (RACC), a Cayman Islands SPAC, entered into a Business Combination Agreement on July 26, 2026 to acquire 100% of OHB Pediatrics Ltd., a clinical-stage biopharmaceutical company developing rugonersen for Angelman syndrome, in exchange for newly issued RACC common stock. The transaction values the Company at a base equity value of $160,000,000, with an Adjusted Equity Value that includes the Company SAFE Amount (principal of $45,000,000 plus accrued interest at 8% per annum). The Closing Consideration equals the Adjusted Equity Value divided by $10.00 per share. Concurrently, RACC is raising $55,000,000 in PIPE financing from qualified institutional buyers at $10.00 per share (or via pre-funded warrants). The transaction is expected to close in the second half of 2026, subject to RACC shareholder approval, regulatory clearances including HSR Act approval, and other customary closing conditions. RACC will domesticate from the Cayman Islands to Delaware prior to closing.
  https://www.sec.gov/Archives/edgar/data/2118032/0001193125-26-316954.txt

## Citations
- 0001193125-26-316954 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526316954